Celia Pinedo-Sierra

Dr. Celia Pinedo-Sierra

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2024 in Open Respiratory Archives
Verified
Journal Article
Open access
CPCelia Pinedo-Sierra
Celia Pinedo-Sierra
ESElena Curto Sánchez
Elena Curto Sánchez
RCRocio Diaz Campos
Rocio Diaz Campos
TVTamara Hermida Valverde
Tamara Hermida Valverde
SSSilvia Sánchez-Cuellar
Silvia Sánchez-Cuellar
ATAna Fernández Tena
Ana Fernández Tena
El asma es una enfermedad inflamatoria crónica que afecta alrededor del 5% de la población mundial y genera unos elevados costes sociosanitarios. Para un manejo adecuado de la enfermedad es necesario un correcto diagnóstico, basado en medidas objetivas de la afectación funcional, así como el control de los síntomas y la valoración del riesgo futuro de exacerbaciones. Se ha estimado que un 18% de los pacientes asmáticos en Europa occidental tienen asma grave y aproximadamente el 50% de ellos cuentan con un mal control. La gravedad del asma se establece en función de las necesidades mínimas de tratamiento de mantenimiento para alcanzar el control. Las guías de práctica clínica de asma recomiendan clasificar a los pacientes graves en asma alérgica (T2); asma eosinofílica (T2) y asma no T2 con el fin de establecer el tratamiento más adecuado. En las últimas décadas se han desarrollado nuevas terapias biológicas que pueden aplicarse según el fenotipo y el endotipo del asma, lo que permite hacer un tratamiento selectivo y personalizado. Estos fenotipos y endotipos pueden modificarse a lo largo del tiempo y por ello, la identificación de biomarcadores capaces de predecir la gravedad, el curso de la enfermedad y la respuesta a un determinado tratamiento parece imprescindible. En el asma se han estudiado una gran cantidad de biomarcadores, pero hasta ahora solo algunos pueden usarse fácilmente en la práctica clínica habitual. La aplicación de las tecnologías ómicas (epigenómica, genómica, transcriptómica, proteómica, metabolómica, lipidómica, etc.) que sirvan para este fin, todavía se encuentran en fase de investigación. Asthma is a chronic inflammatory disease that affects about 5% of the world's population and generates high health and social costs. Proper management of the disease requires a correct diagnosis, based on objective measures of functional impairment, as well as symptom control and assessment of the future risk of exacerbations. It has been estimated that 18% of asthma patients in Western Europe have severe asthma and approximately 50% of them have poor control. The severity of asthma is established based on the minimum maintenance treatment needs to achieve control. Asthma clinical practice guidelines recommend classifying severe patients into allergic asthma (T2); eosinophilic asthma (T2) and non-T2 asthma in order to establish the most appropriate treatment. In recent decades, new biological therapies have been developed that can be applied according to the phenotype and endotype of asthma, allowing for selective and personalized treatment. These phenotypes and endotypes can change over time and therefore, the identification of biomarkers capable of predicting the severity, the course of the disease and the response to a given treatment seems essential. A large number of biomarkers have been studied in asthma, but so far only a few can be readily used in routine clinical practice. The application of omics technologies (epigenomics, genomics, transcriptomics, proteomics, metabolomics, lipidomics, etc.) for this purpose is still in the research phase.

13 February 2025 in Journal of Asthma
Verified
Journal Article
Open access
Eva María Martínez PérezEva María Martínez Pérez
Eva María Martínez Pérez
CPCelia Pinedo-Sierra
Celia Pinedo-Sierra
LMLuis Puente MAestu
Luis Puente MAestu
MMMariana Muñoz-Esquerre
Mariana Muñoz-Esquerre
AFAna Gómez-Bastero Fernández
Ana Gómez-Bastero Fernández
SQSantiago Quirce
Santiago Quirce
Asthma and severe asthma are problems affecting all age groups, but asthma is frequently undiagnosed in the elderly, due to the poor perception of airflow limitation, lack of fitness, and presence of multiple comorbidities.Even so, the proportion of patients with severe asthma aged ≥65 is significant, and data on efficacy of asthma medications in the elderly are sometimes limited. We report here the effectiveness and safety of mepolizumab (an IL-5 inhibitor) in elderly (≥ 65 years) patients. The REDES study was an observational, multicenter study of the effectiveness and safety of mepolizumab 100mg SC every 4 weeks in 318 severe asthma patients in Spain. This post-hoc analysis compares the effectiveness and safety of patients ≥65 years old to patients <65 years after 12 months of mepolizumab treatment. 27% of patients were ≥65 years old, compared with 73% of patients <65 years. Elderly patients showed a trend towards less frequent comorbid nasal polyps (p = 0.06) and a lower proportion of atopic sensitization (as detected by prick test or specific IgE) (p = 0.02). Similar improvements were noted in ACT score (p < 0.0001), comparable exacerbation reductions (p < 0.0001) and lung function parameters (p < 0.04 in elder group and p < 0.0001 in younger elder group), although an apparent greater reduction of OCS daily dose was observed in elder patients (p = 0.0002). No new safety signals were reported in the elderly population. This study further supports mepolizumab as an effective and well tolerated therapy in the difficult to treat population of elderly patients with severe asthma.

12 November 2026 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
CLCristina Matesanz López
Cristina Matesanz López
CPCelia Pinedo-Sierra
Celia Pinedo-Sierra
JBJosé Manuel Padilla Brito
José Manuel Padilla Brito
SPSonia Pascual
Sonia Pascual
ERElizabeth Manuely González Revilla
Elizabeth Manuely González Revilla
ANAsuncion Nieto
Asuncion Nieto
Drug-induced sarcoid-like reactions (DISRs) are uncommon granulomatous disorders that develop in temporal association with drug exposure and closely resemble sarcoidosis clinically, radiologically, and histologically. Their recognition has become increasingly relevant with the expanding use of immune-modulating and targeted therapies. Immune checkpoint inhibitors and tumor necrosis factor-alpha inhibitors are among the best-documented causes, while sarcoid-like reactions have also been reported with interferons, dupilumab, BRAF/MEK inhibitors, and other biologic and targeted agents. Thoracic involvement is particularly common and typically manifests as bilateral hilar or mediastinal lymphadenopathy, with or without pulmonary parenchymal abnormalities. In patients with cancer, these findings may mimic disease progression and lead to inappropriate modification of effective anticancer therapy. Imaging findings are not specific, and histological confirmation may therefore be necessary when the differential diagnosis would alter clinical management. Management should be individualized according to clinical severity, organ involvement, diagnostic certainty, and the importance of continuing the suspected drug. Observation or continuation of therapy may be appropriate in selected asymptomatic or limited cases, whereas drug withdrawal and systemic corticosteroids may be required in symptomatic or multisystem disease. This narrative review summarizes current evidence on DISRs, with particular emphasis on pulmonary and intrathoracic manifestations, associated drug classes, diagnostic challenges, management, and outcomes. A respiratory-focused diagnostic pathway is proposed, integrating comparison with prior imaging, targeted microbiological sampling, selective bronchoscopic or other tissue biopsy, and assessment of competing diagnoses, including malignancy and immune checkpoint inhibitor pneumonitis. The pathway also supports individualized decisions on observation, drug continuation, or withdrawal; it is not a validated diagnostic instrument.

15 October 2026 in Respiratory Research
Verified
Journal Article
Open access
PDF file
APAlicia Padilla-Galo
Alicia Padilla-Galo
CRCarlos Martinez Rivera
Carlos Martinez Rivera
ATA. Trisán-Alonso
A. Trisán-Alonso
AFAna Gómez-Bastero Fernández
Ana Gómez-Bastero Fernández
AMAlvaro Martinez Mesa
Alvaro Martinez Mesa
MAMARINA BLANCO APARICIO
MARINA BLANCO APARICIO
Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare systemic inflammatory disease in which severe asthma frequently represents the predominant c